Related references
Note: Only part of the references are listed.Prostate high dose -rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy
Gerard Morton et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Dosimetric evaluation of MRI-to-ultrasound automated image registration algorithms for prostate brachytherapy
Amani Shaaer et al.
BRACHYTHERAPY (2020)
Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer
Zaid A. Siddiqui et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
High-dose-rate brachytherapy as monotherapy for prostate cancer: The impact of cellular repair and source decay
Christopher J. Tien et al.
BRACHYTHERAPY (2019)
Single-fraction brachytherapy as monotherapy for early-stage prostate cancer: The UCSF experience
Melody J. Xu et al.
BRACHYTHERAPY (2019)
Reoxygenation during radiotherapy in intermediate-risk prostate cancer
Stephane Supiot et al.
RADIOTHERAPY AND ONCOLOGY (2019)
Single Fraction High-Dose-Rate Brachytherapy: Too Good to Be True?
Gerard C. Morton et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
MRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trial
Yasir Alayed et al.
RADIOTHERAPY AND ONCOLOGY (2019)
Clinical evaluation of an MRI-to-ultrasound deformable image registration algorithm for prostate brachytherapy
Amani Shaaer et al.
BRACHYTHERAPY (2019)
High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: Toxicity and 6-year biochemical results
Pedro J. Prada et al.
BRACHYTHERAPY (2018)
High dose-rate brachytherapy in the treatment of prostate cancer
Lucas C. Mendez et al.
TRANSLATIONAL ANDROLOGY AND UROLOGY (2018)
Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy
Daniel J. Krauss et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer
Peter Hoskin et al.
RADIOTHERAPY AND ONCOLOGY (2017)
High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: Toxicity and long-term biochemical results
Pedro J. Prada et al.
RADIOTHERAPY AND ONCOLOGY (2016)
High-dose-rate brachytherapy as monotherapy for prostate cancer
D. Jeffrey Demanes et al.
BRACHYTHERAPY (2014)
A comparative study of quality of life in patients with localized prostate cancer treated at a single institution: Stereotactic ablative radiotherapy or external beam plus high dose rate brachytherapy boost
Joelle Helou et al.
RADIOTHERAPY AND ONCOLOGY (2014)
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
Mack Roach et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
A Trotti et al.
SEMINARS IN RADIATION ONCOLOGY (2003)
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer
JT Wei et al.
UROLOGY (2000)
Share Paper
